Flatiron Health IPO

Flatiron Health was a healthcare technology company focused on accelerating cancer research and improving patient care through real-world data and evidence generation. The company built a comprehensive oncology cloud platform that captured and structured clinical data from electronic health records, enabling pharmaceutical companies, researchers, and healthcare providers to gain insights into cancer treatment patterns and outcomes. Flatiron's platform aggregated data from hundreds of cancer clinics and hospitals across the United States, creating one of the largest real-world oncology datasets.

The company's technology transformed unstructured clinical notes and medical records into structured, research-grade data that could be used for drug development, regulatory submissions, and clinical decision support. Flatiron partnered with major pharmaceutical companies to conduct real-world evidence studies and helped the FDA approve new cancer treatments based on real-world data rather than traditional clinical trials. Roche acquired Flatiron Health for $1.9 billion in 2018, recognizing the strategic value of its data platform and expertise in oncology informatics for advancing personalized cancer care and drug development.